|  |
| --- |
| **Cancer Incidence and Mortality in Massachusetts 2015-2019** |
| **Statewide Report** |
|  |
|  |
|  |


Massachusetts Cancer Registry

Office of Data Management and Outcomes Assessment

Office of Population Health

Massachusetts Department of Public Health

*September 2023*

****

|  |
| --- |
| **Cancer Incidence and Mortality in Massachusetts 2015-2019** |
| **Statewide Report** |
|  |
|  |
| Maura T. Healey, Governor |

Kimberley Driscoll, Lieutenant Governor

Kathleen Walsh, Secretary of Health and Human Services

Robert Goldstein, Commissioner of Public Health

Sai Cherala, Acting Assistant Commissioner

Susan T. Gershman, Director, Massachusetts Cancer Registry

Massachusetts Department of Public Health

*September 2023*

**Acknowledgements**

This report was prepared by Joshua Nyambose, Senior Epidemiologist, Massachusetts Cancer Registry, and Massachusetts Cancer Registry staff. Special thanks are given to Richard Knowlton for his diligent work in preparing the data for this report. Thanks are given to Sharon Pagnano of the Massachusetts Registry of Vital Records and Statistics for providing the mortality data.

**Massachusetts Cancer Registry Staff**

Susan T. Gershman, MS, MPH, PhD, CTR, *Director*

Amarilis Cora, *Office Support Specialist*

Nancy Donovan, MA, CTR, *Cancer Registrar/Quality Control Coordinator*

*Heatha Gomes, Cancer Registrar*

Nancy Klein, CTR, *Operations Manager*

Richard Knowlton, MS, *Epidemiologist*

Joshua Nyambose, PhD*, Epidemiology Supervisor*

Mary Mroszczyk, CTR, *Geocoding/ Special Projects Coordinator*

Jeremiah Nesser, *Technical Assistant for Special Projects*

Barbara J. Rhodes, CMA, CTR, *Cancer Registrar/Death Clearance Coordinator*

Pamela Shuttle, CTR, RHIT, *Cancer Registrar/Non-Hospital Reporting Coordinator*

Stacie Sullivan*, Cancer Registrar*

Hung Tran, *Software Developer*

**Massachusetts Cancer Registry Advisory Committee**

Lindsay Frazier, MD, ScM *(Chair)*

Al Ozonoff, MA, PhD

Sigalle Reiss, MPH, RS/REHS

Ingrid Stendhal, CTR

Susan Sturgeon, DrPH, MPH

Michelle A. Williams, MS, SM, ScD

Torunn Yock, MD, MCH

Martie Carnie, Community Representative

Deborah Dillon, MD

Joanna Haas, MD

Michael Hassett, MD, MPH

Joseph Jacobson, MD

Benjamin C. James, MD, MS, FACS

Nancy Keating, MD, MPH

Carol Lowenstein, CTR, MBA

Larissa Nekhlyudov, MD, MPH

The data in this report are intended for public use and may be reproduced without permission. Proper acknowledgement of the source is requested.

For further information, please visit the following:

|  |  |
| --- | --- |
| Massachusetts Cancer Registry……………………………  Occupational Health Surveillance…………………………  Bureau of Environmental Health………………………….  Comprehensive Cancer Control Program……………..  Massachusetts Department of Public Health………. | <https://www.mass.gov/massachusetts-cancer-registry>  <https://www.mass.gov/orgs/occupational-health-surveillance-program>  <https://www.mass.gov/orgs/bureau-of-environmental-health>  <https://www.mass.gov/comprehensive-cancer-control-program>  <https://www.mass.gov/orgs/department-of-public-health> |

We acknowledge the Centers for Disease Control and Prevention for its support of the staff under cooperative agreement 1NU58DP007092-01-00 and the National Cancer Institute under contract HHSN261201800008l awarded to the Massachusetts Department of Public Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention nor the National Cancer Institute.

Table of Contents

**Preface1**

**Basic Cancer Facts 2**

**Executive Summary4**

Cancer Incidence (New cases) 8

Table 1. New Cancer Cases by Sex for Leading Sites, Massachusetts, 2015-20198

Figure 1. Top 10 Cancers Among Females in Massachusetts, 2015-20199

Figure 2. Top 10 Cancers Among Males in Massachusetts, 2015-20199

Figure 3. Percent of All Cancer Cases by Age Group in Massachusetts Males, 2015-20199

Figure 4. Percent of All Cancer Cases by Age Group in Massachusetts Females, 2015-20199

Figure 5. Comparison of Massachusetts and US Males Average Annual Age-adjusted Incidence by Cancer Site/Type, 2015-201910

Figure 6. Comparison of Massachusetts and US Females Average Annual Age-adjusted Incidence by Cancer Site/Type, 2015-201911

Figure 7. Trends in Total Number of Massachusetts Cancer Cases and Incidence Rates, 2000-201912

Figure 8. Trends in Massachusetts Incidence Rates for All Cancers Combined by Sex, 2015-2019 12

Cancer Mortality13

Table 2. Cancer Deaths by Sex for Leading Cancer Sites in Massachusetts, 2015-201913

Figure 9. Top 10 Causes of Cancer Deaths Among Females in Massachusetts, 2015-201914

Figure 10. Top 10 Causes of Cancer Deaths Among Males in Massachusetts, 2015-201914

Figure 11. Percent of All Cancer Deaths by Age Group in Massachusetts Males, 2015-201915

Figure 12. Percent of All Cancer Deaths by Age Group in Massachusetts Females, 2015-201915

Figure 13. Trends in Total Number of Massachusetts Cancer Deaths and Death Rates, 2000-201915

Figure 14. Trends in Massachusetts Mortality Rates for All Cancers Combined by Sex, 2015-201916

Stage at Diagnosis for Selected Cancers17

Figure 15. Breast Cancer Stage at Diagnosis in Massachusetts, 2015-201917

Figure 16. Prostate Cancer Stage at Diagnosis in Massachusetts, 2015-201917

Figure 17. Colon and Rectum Cancer Stage at Diagnosis in Massachusetts, 2015-201918

Figure 18. Lung and bronchus Cancer Stage at Diagnosis in Massachusetts, 2015-201918

Cancer Incidence and Mortality in Massachusetts by County19

Figure 19. Incidence Rates for all Cancer Sites in Massachusetts by County, 2015-201919

Figure 20. Mortality Rates for all Cancer Sites in Massachusetts by County, 2015-201919

Cancer Disparities and Health Equity20

Figure 21. Age-Adjusted Cancer Incidence Rates in Massachusetts by Sex and Race/Ethnicity,

2015-201920

Figure 22. Age-Adjusted Cancer Mortality Rates in Massachusetts by Sex and Race/Ethnicity,

2015-201921

Figure 23. Cancer Incidence Rates in Massachusetts Males by Race/Ethnicity, 2015-2019, Five Most Common Cancers22

Figure 24. Cancer Incidence Rates in Massachusetts Females by Race/Ethnicity, 2015-2019, Five Most Common Cancers23

Figure 25. Cancer Incidence in Massachusetts Females by Year at Diagnosis and Race/Ethnicity,

2015-201924

Figure 26. Cancer Incidence in Massachusetts Males by Year at Diagnosis and Race/Ethnicity,

2015-201924

Figure 27. Cancer Mortality in Massachusetts Females by Year of Death and Race/Ethnicity,

2015-201925

Figure 28. Cancer Mortality in Massachusetts Males by Year of Death and Race/Ethnicity,

2015-201925

Table 3: Ten Most Common Causes of Cancer Deaths Among Massachusetts Females by Race/Ethnicity, 2015-201926

Table 4: Ten Most Common Causes of Cancer Deaths Among Massachusetts Males by Race/Ethnicity, 2015-201927

Data sources and Online Visualization Tools 28

**Appendices** **29**

Appendix I. New Cancer Cases and Incidence Rates by Cancer Site and Sex, Massachusetts, 2015-201929

Appendix II. Number of Cancer Deaths and Death Rates by Cancer Site and Sex, Massachusetts,

2015-201930

Appendix III. Technical Notes31

Appendix IV. DPH Cancer Programs Health Equity Initiatives34

**References** **38**

**Preface**

The Massachusetts Cancer Registry (MCR) Incidence and Mortality Statewide Report 2015-2019 presents a summary of cancer incidence (new cases) and mortality (deaths) for the Commonwealth of Massachusetts. The main objective of the report is to provide cancer data by age, sex, race/ethnicity, stage at diagnosis, and county, as well as to highlight trends in Massachusetts cancer rates for 2015-2019. The report also compares Massachusetts incidence and mortality rates to US rates. The collection and analysis of population-based cancer data help determine the burden of cancer in Massachusetts. These data can be used by public health professionals, cancer control programs, policy makers, researchers, and others to develop, implement, and evaluate cancer prevention and control activities, to support cancer-related research, and to describe the burden of cancer in Massachusetts.

The MCR collects reports of newly diagnosed cases of cancer and routinely compiles summaries of cancer incidence and mortality data. All Massachusetts health care facilities and providers who diagnose or treat patients with cancer are required, by law,[[1]](#endnote-1) to report each case of malignant disease and benign brain-related tumor disease to the MCR within six months of diagnosis or first contact, except for basal and squamous cell skin cancer and *in situ* (non-invasive) cervical cancer. Due to the complexity of the cancer data collection and quality control process, there is a delay between the time a new cancer is diagnosed and the time the data are ready for analysis. The typical delay is about 24 months after the end of the calendar year of diagnosis. This report, *Cancer Incidence and Mortality in Massachusetts, 2015-2019: Statewide Report* is produced annually with the most recently available statewide data. This report will focus on the leading causes of new cancers and cancer deaths in men and women in Massachusetts. Beginning with the 2014-2018 statewide report, each table or chart is accompanied by text to explain the data. This report will also include new sections such as preface, basic cancer facts, stage at diagnosis, cancer incidence and mortality by county, and cancer disparities and health equity.

Another report, *Cancer Incidence in Massachusetts: City and Town Supplement*, is also produced periodically by the MCR and contains information for the 351 cities and towns in Massachusetts.

MCR data quality, completeness and timeliness are evaluated annually by the Centers for Disease Control and Prevention / National Program of Cancer Registries (CDC/NPCR), the National Cancer Institute/Surveillance, Epidemiology, and End Results Program (NCI/SEER) and the North American Association of Central Cancer Registries (NAACCR). MCR data routinely meets national data quality standards. However, completeness may be higher or lower for specific cancer types, geographic areas, or demographic subgroups. Also, it is not unusual for the number of cancer cases and incidence rates to vary from year to year, especially for smaller geographic areas and demographic subgroups.

Massachusetts cancer death data were provided by the Registry of Vital Records and Statistics (RVRS) at Massachusetts Department of Public Health (MDPH). RVRS receives certificates of death from local vital statistics offices and from other states when a Massachusetts resident dies outside of the state. Cancer death data in this report were categorized by the underlying cause of death.

Electronic versions of this and other reports may be found online at [www.mass.gov/dph/mcr](http://www.mass.gov/dph/mcr).

**Basic Cancer Facts**

Cancer is the name given to a collection of related diseases that are usually named after tissues or organs where the cancers form. For instance, breast cancer that starts in the breast is still called breast cancer even if it spreads (metastasizes) to other parts of the body.[[2]](#endnote-2) Cancer is not a single disease but a collection of diseases including for example, lung and bronchus, prostate, breast, colon and rectum, and brain. Cancer occurs when some of the body’s cells begin to divide without stopping and spread into surrounding tissues. Screening can help prevent cancer deaths and morbidity and when caught early some cancers can be prevented.[[3]](#endnote-3)

**Who is at risk of Developing Cancer?**

One of the major risk factors of cancer is older age. Eight in ten of cancers in the United States are diagnosed in people over 55 years of age or older and 57% are 65 years or older. In addition to age, the risk of cancer is increased by certain behaviors including cigarette smoking, excess body weight, drinking alcohol, and poor or unhealthy diet. In the United States, the lifetime risk of developing cancer is 40 out of 100 in men and 39 out of 100 in women.[[4]](#endnote-4) It is important to note that these probabilities are estimated based on the overall experience of the general population and may overestimate or underestimate individual risk because of differences in exposures such as smoking, family history, and/or genetic susceptibility.

**What are Cancer Risk Factors?**

A cancer risk factor is anything that increases a person’s chance of developing cancer and a protective factor is anything that decreases a person’s chance of developing cancer. Risk factors are categorized into two main groups, those that are known to increase the risk of cancer and those that may affect the risk of cancer. Examples of known cancer risk factors include cigarette smoking and tobacco use, infections, radiation, and immunosuppressive medicines after organ transplant. Factors that may affect the risk of cancer include diet, drinking alcohol, physical activity, obesity, diabetes, and being exposed to chemicals and other substances in the environment, and ultraviolet (UV) radiation. A person’s risk of developing cancer often does not increase due to one risk factor but usually results from a complex interaction of several factors, sometimes over long periods of time.[[5]](#endnote-5)

**Can Cancer be Prevented?**

Some cancer risk factors can be avoided while many others cannot. For example, both smoking and inheriting certain genes are risk factors for some types of cancers, but only smoking can be avoided. According to the American Cancer Society (ACS) at least 42% of newly diagnosed cancers in the United States, about 820,000 cases in 2023, are potentially avoidable. These cancers include 19% of all cancers that are caused by smoking and 18% that are caused by a combination of excess body weight, excess alcohol consumption, poor nutrition, and lack of physical activity. Some cancers that are caused by infection agents can be prevented through behavioral changes to avoid infection or through vaccination or by treating the infection. In addition, screening can help reduce mortality for cancers including colon and rectum, breast, cervical, prostate, and lung and bronchus. Screening can also detect some cancers early when treatment is often more successful.[[6]](#endnote-6)

**How is Cancer Staged?**

Staging describes the extent or spread of cancer at the time of diagnosis and guides decisions about treatment. For most cancers, stage is based on the size or extent of the primary tumor and whether the cancer has spread to nearby lymph nodes or other parts of the body.[[7]](#endnote-7) Cancer staging is categorized into five main groups: In situ, local, regional, distant, and unknown.[[8]](#endnote-8) Relative survival is an estimate of the percentage of patients who would be expected to survive the effects of their cancer, and it excludes the risk of dying from other causes. The earlier a cancer is diagnosed, the better chance a person has of surviving. For example, between 2012 and 2018 the five-year survival for colon and rectum cancer diagnosed at the localized stage in the United States was 90.9%, whereas, when the cancer was diagnosed at the distant stage, the five-year relative survival was only 15.1%.[[9]](#endnote-9)

**In situ:**  Cancer is confined to the layer of cells where it began growing and has not spread

**Local:** Cancer is limited to the place where it started, with no sign that it has spread

**Regional**: Cancer has spread to nearby lymph nodes, tissues, or organs

**Distant:** Cancer has spread to distant parts of the body

**Unknown**: Insufficient information is available to determine the stage or extent of the disease

**What are the Costs of Cancer?**

The cost of cancer can be measured in several ways including direct medical costs (total of all health care expenditures), as well as indirect costs (such as lost earnings due to missed work from illness or premature death). In addition, cancer care costs and lost income due to time away from work during treatment and recovery can lead to medical financial hardship for cancer patients and their families. Many cancer survivors report financial hardship associated with cancer. These include difficulties paying medical bills, distress and worry about medical bills, or delaying or forgoing medical care due to cost. Lack of health insurance is strongly associated with medical financial hardship and prevents many Americans from receiving optimal cancer prevention, early detection, and treatment. According to the National Cancer Institute, cancer-related direct medical costs in the US were estimated to be $183 billion in 2015 and are projected to increase to $246 billion by 2030, a 34% increase based only on population growth and aging.[[10]](#endnote-10)

**Executive Summary**

*Cancer Incidence and Mortality in Massachusetts, 2015-2019: Statewide Report* presents cancer incidence and mortality data for the Commonwealth from 2015 through 2019. The report includes numbers and rates for 24 types of cancer, information on age-specific patterns, an examination of patterns by race/ethnicity, and a comparison of Massachusetts and national cancer rates. Data are provided on invasive cancers only with the exceptions of urinary bladder (which includes in situ and invasive cancers combined) and in situ breast cancer.

**All Cancers Combined Incidence (New cases)**

* Between 2015 and 2019, there were 197,985 new cancer cases in Massachusetts, an average of 39,597 cases per year
* During this period there were:
  + 97,311 cancer cases among males
  + 100,698 cancer cases among females
  + The age-adjusted incidence rate for all cancers combined was:
* 501.5 per 100,000 in males
* 446.7 per 100,000 in females

**All Cancers Combined Mortality (Deaths)**

* Cancer is the most common cause of death in Massachusetts and the United States, accounting for nearly one of every four deaths
* Between 2015 and 2019, there were 63,589 cancer deaths in Massachusetts, an average of 12,718 deaths per year
* During this period there were:
  + 32,503 cancer deaths among males
  + 31,086 cancer deaths among females
  + The age-adjusted mortality rate for all cancer deaths combined was:
* 177.7 per 100,000 in males
* 127.6 per 100,000 in females

**Cancer Incidence**

Breast cancer was the leading cancer among Massachusetts females between 2015 and 2019, followed by lung and bronchus, corpus uteri & uterus, colon and rectum, and thyroid cancers. Among males, prostate cancer was the leading cancer, followed by lung and bronchus, colon and rectum, urinary bladder, and melanoma cancers. Nationally, breast cancer was also the leading cancer among females and prostate cancer was the leading cancer among males. In Massachusetts, the age-adjusted cancer incidence rate for all cancer sites combined decreased in both males and females between 2015 and 2019. However, this decrease was not statistically significant.

**Cancer Mortality**

Lung and bronchus cancer was the leading cause of cancer deaths among Massachusetts females between 2015 and 2019, followed by breast, pancreas, and colon and rectum cancers. Among males, lung and bronchus cancer was also the leading cause of cancer deaths, followed by prostate, pancreas, and colon and rectum cancers. Nationally, lung and bronchus cancer was also the leading cause of cancer deaths in both males and females. In Massachusetts, the age-adjusted cancer mortality rate for all cancer sites combined significantly decreased by 1.8% per year in males and 2.7% per year in females between 2015 and 2019.

**Cancer Trends 2015-2019**

**Statistically Significant Incidence Trends – Males**

|  |  |  |
| --- | --- | --- |
| **Cancer** | **Trend** | **% Decrease Per Year** |
| Colon and rectum cancer | Falling ↓ | 1.7% |
| Kidney cancer | Falling ↓ | 2.6% |
| Thyroid cancer | Falling ↓ | 6.0% |

|  |  |  |
| --- | --- | --- |
| **Cancer** | **Trend** | **% Increase Per Year** |
| Hodgkin Lymphoma | Rising ↑ | 5.9% |
| Prostate Cancer | Rising ↑ | 4.0% |

**Statistically Significant Mortality Trends – Males**

|  |  |  |
| --- | --- | --- |
| **Cancer** | **Trend** | **% Decrease Per Year** |
| All invasive cancers | Falling ↓ | 1.8% |
| Lung and bronchus cancer | Falling ↓ | 4.7% |
| Kidney cancer | Falling ↓ | 7.7% |

**Statistically Significant Incidence Trends – Females**

|  |  |  |
| --- | --- | --- |
| **Cancer** | **Trend** | **% Decrease Per Year** |
| Colon and rectum cancer | Falling ↓ | 4.3% |
| Non-Hodgkin Lymphoma | Falling ↓ | 1.4% |
| Thyroid | Falling ↓ | 5.6% |

**Statistically Significant Mortality Trends – Females**

|  |  |  |
| --- | --- | --- |
| **Cancer** | **Trend** | **% Decrease Per Year** |
| All invasive cancers | Falling ↓ | 2.7% |
| Lung and bronchus cancer | Falling ↓ | 4.4% |
| Colon and rectum cancer | Falling ↓ | 5.3% |
|  |  |  |

**Cancer Disparities and Health Equity**

Although cancer can affect all groups in Massachusetts, the burden of the disease is greater in certain groups compared to others. Black non-Hispanic communities and other populations disproportionately impacted by cancer experience greater obstacles to cancer prevention, detection, treatment, and survival, including systemic racial disparities that are usually not connected with cancer. These include structural racism, poverty, lack of access to affordable healthy foods, jobs with inadequate pay, low quality education and housing, and unsafe environments.[[11]](#endnote-11) Cancer disparities are defined as differences in cancer measures including incidence, mortality, stage at diagnosis and cancer screening rates. Typically, these cancer disparities are considered by race or ethnic group. However, there are other factors that characterize cancer disparities including disability status, gender, income, education, sexual orientation, and other characteristics.[[12]](#endnote-12) According to the CDC, health equity is defined as the state in which everyone has a fair and just opportunity to attain their highest level of health.[[13]](#endnote-13) Health inequities can be reduced through focused and ongoing efforts by everyone to address historical and current injustices, overcome economic, social, and other obstacles to health and healthcare, and eliminate preventable health disparities.[[14]](#endnote-14) Appendix IV presents several programs at the MDPH aimed at implementing initiatives to address cancer disparities and health inequities in Massachusetts.

Racial and ethnic disparities in the cancer burden generally reflect long-standing inequities in socio-economic status (SES) and access to high-quality health care, due in part to historical and persistent structural racism in the US experienced by all people of color.[[15]](#endnote-15) According to the US Census Bureau 9.4% of the Massachusetts population lived below the federal poverty line in 2019. However, major differences emerge when poverty rates were stratified by race/ethnicity. Nearly one in five (17.6%) of Black non-Hispanics and 19.6% of Hispanics in Massachusetts lived below the poverty line in 2019, compared to 6.5% of White non-Hispanics and 10.6% of Asian non-Hispanics.[[16]](#endnote-16) Consequently, cancer mortality rates are also generally higher among people with lower SES compared to people with higher SES. According to the ACS lung cancer deaths were 4.6 times higher among US men with 12 or fewer years of education than among men with 4-year college degrees in 2016, in part due to a higher prevalence of cancer risk factors such as tobacco smoking, poor diet, and lack of physical activity in people with lower SES.[[17]](#endnote-17) For example, in 2019 the tobacco smoking rate was 25.2% among US adults with less than a high school education compared to 6.1% among those who graduated from college or technical school.[[18]](#endnote-18) Similarly, a greater proportion of Massachusetts adults with less than high school education were cigarette smokers in 2019.[[19]](#endnote-19) One possible explanation for the increased smoking among those from lower SES or low education status is because of targeted marketing of tobacco products to people in low-income neighborhoods by tobacco companies.[[20]](#endnote-20)

People with fewer resources also have less access to high-quality health care because of inadequate health insurance, and lack of adequate health care providers in low-income neighborhoods, financial, structural, and personal obstacles, low health literacy, and delays in the dissemination of advances in early detection and treatment to low-income areas.[[21]](#endnote-21) In addition, people of lower SES are more likely to live and work in areas with limited opportunities for physical activity and availability of fresh fruits and vegetables, have a higher risk of exposure to cancer-causing infections and harmful exposures.[[22]](#endnote-22) As a result, people of lower SES have a higher likelihood of developing cancer, being diagnosed at a late stage, less likely to receive the standard of care, and are more likely to have lower survival.[[23]](#endnote-23)

Within SES groups, disparities by race and ethnicity persist as people of color are more likely to receive lower-quality health care than White people even when health insurance status, age, severity of disease, and health status are comparable. In addition, social inequalities, such as language barriers and provider bias, can affect interactions between patients and physicians and contribute to miscommunication and receipt of substandard care. Racial and ethnic disparities also reflect cultural influences on cancer risk factor behaviors. For example, lung cancer rates in the US are lower among Hispanic or Asians than in other racial/ethnic groups because Hispanics and Asians as a whole, are historically less likely to smoke. On the other hand, because a relatively large proportion of Hispanics or Asians are recent immigrants in US, they generally have higher rates of cancer related to infectious agents such as stomach cancer, reflecting higher infection prevalence such as Helicobacter pylori in their native countries.[[24]](#endnote-24)

Although there are many contributing factors to racial/ethnic disparities in cancer burden, this report will focus on disparities in incidence and mortality by race/ethnicity, sex, age, stage at diagnosis, and geographic location in Massachusetts.

**Females Incidence**

* + White non-Hispanic females had significantly higher age-adjusted incidence rates of all cancers combined than Black non-Hispanic, Asian non-Hispanic, and Hispanic females.
  + Asian non-Hispanic females had the lowest age-adjusted incidence rate for all cancers combined than other racial/ethnic groups.

**Males Incidence**

* Among males, Black non-Hispanics and White non-Hispanics had significantly higher age-adjusted incidence rates for all cancers combined than Asian non-Hispanic and Hispanic males.
* There was no significant difference in the incidence rates for all cancers combined between White non-Hispanic and Black non-Hispanic males.
* Asian non-Hispanic males had the lowest age-adjusted incidence rate for all cancers combined than other racial/ethnic groups.

**Females Mortality**

* White non-Hispanic females had the highest all cancers combined mortality rates, significantly higher than for Asian non-Hispanic, Black non-Hispanic, and Hispanic females.
* Asian non-Hispanic females had the lowest age-adjusted mortality rate for all cancers combined than other racial/ethnic groups.

**Males Mortality**

* White non-Hispanic males had a significantly higher mortality rate for all cancers combined than other racial/ethnic groups.
* Black non-Hispanic males had a significantly higher mortality rate for all cancers combined than Asian non-Hispanic and Hispanic males.
* Asian non-Hispanic males had the lowest age-adjusted mortality rate for all cancers combined compared with other racial/ethnic groups.

**Massachusetts vs. National Rates**

**Incidence**

* The overall age-adjusted incidence rates for all cancers combined in Massachusetts were lower than the national rates among males. However, the difference was not statistically significant.
* Among females, the overall age-adjusted incidence rates for all cancers combined were significantly higher in Massachusetts than the national rates.

**Mortality**

* The overall age-adjusted mortality rates for all cancers combined in Massachusetts were significantly lower than the national rates for both males and females.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Cancer Incidence (New Cancer Cases)**  Table 1. New Cancer Cases by Sex for Leading Sites, Massachusetts, 2015-2019 | | | | | | |
| **FEMALES** |  | | | |  | |
| **CANCER SITE** | **NUMBER OF NEW CASES** | | | | **% OF ALL CANCER CASES** | |
| Breast | | | 30,412 | | | 30.2 |
| Lung & Bronchus | | | 14,345 | | | 14.2 |
| Corpus Uteri &Uterus, NOS | | | 7,015 | | | 7.0 |
| Colon & Rectum | | | 6,896 | | | 6.8 |
| Thyroid | | | 4,893 | | | 4.9 |
| Melanoma of the Skin | | | 4,410 | | | 4.4 |
| Non-Hodgkin Lymphoma | | | 3,647 | | | 3.6 |
| Pancreas | | | 2,947 | | | 2.9 |
| Urinary Bladder | | | 2,549 | | | 2.5 |
| Kidney & Renal Pelvis | | | 2393 | | | 2.4 |
| All others | | | 21,191 | | | 21.0 |
| **TOTAL** | | | **100,698** | | | **100.0** |
|  | | | | | | |
| **MALES** | |  | |  | | |
| **CANCER SITE** | | **NUMBER OF NEW CASES** | | **% OF ALL CANCER CASES** | | |
| Prostate | | 24,614 | | 25.3 | | |
| Lung & Bronchus | | 12,381 | | 12.7 | | |
| Colon & Rectum | | 7,210 | | 7.4 | | |
| Urinary Bladder | | 7,042 | | 7.2 | | |
| Melanoma of Skin | | 5,570 | | 5.7 | | |
| Non-Hodgkin Lymphoma | | 4,487 | | 4.6 | | |
| Kidney & Renal Pelvis | | 4,325 | | 4.4 | | |
| Oral Cavity & Pharynx | | 3,661 | | 3.8 | | |
| Pancreas | | 3,130 | | 3.2 | | |
| Leukemia | | 3,121 | | 3.2 | | |
| All others | | 21,770 | | 22.4 | | |
| **TOTAL** | | **97,311** | | **100.0** | | |

Source: Massachusetts Cancer Registry

For more information, visit the Massachusetts Cancer Registry Web Query at: <https://www.cancer-rates.info/ma/>

* Almost one third (30.2%) of all new cancers among females in Massachusetts between 2015 and 2019 were breast cancers, followed by lung and bronchus (14.2%), corpus uteri & uterus (7.0%), colon and rectum (6.8%), and thyroid cancers (4.9%).
* Nationally, breast cancer was also the leading cause of cancer among females.
* Among males, prostate cancer was the leading cause of cancer, with a quarter (25.3%) of all new cancers in males, followed by lung and bronchus (12.7%), colon and rectum (7.4%), urinary bladder (7.2%), and melanoma of the skin (5.7%) cancers.
* Nationally, prostate cancer was also the leading cause of cancer among males.

Source: Massachusetts Cancer Registry

* Between 2015 and 2019 breast cancer was the leading cause of new cancers in Massachusetts females, with an age-adjusted incidence rate of 138.9 per 100,000.
* Among males, prostate cancer was the leading cause of new cancers, with an age-adjusted incidence rate of 116.9 per 100,000 during this period.

Source: Massachusetts Cancer Registry, Surveillance Epidemiology and End Results (SEER\*Stat)

* Cancer for all sites combined was most frequently diagnosed among Massachusetts males and females aged 55-64 and 65-74 years.
* Less than one percent of all cancers were diagnosed among Massachusetts males and females younger than 20 years of age.



Percent Below and Above US Incidence Rate


Source: Massachusetts Cancer Registry and CiNA Explorer: An interactive tool for quick access to key NAACCR cancer statistics based on the Cancer in North America (CiNA) dataset from the North American Association of Central Cancer Registries

Available from (https://apps.naaccr.org/explorer)

Rates are age-adjusted to the 2000 U.S. Standard Population

* Among males, there were several cancers with statistically significant lower or higher incidence rates in Massachusetts than in the US between 2015 and 2019. Only those with statistically significant differences are presented in the next two bullets:
* Cancers with significantly lower incidence rates in Massachusetts than national rates included leukemia, kidney, and colon and rectum.
* Cancers with significantly higher incidence rates in Massachusetts than national rates included thyroid, esophagus, urinary bladder, brain, liver, and pancreas.

Percent Below and Above US Incidence Rate



Percent Below and Above US Incidence Rate

Source: Massachusetts Cancer Registry and CiNA Explorer: An interactive tool for quick access to key NAACCR cancer statistics based on the Cancer in North America (CiNA) dataset from the North American Association of Central Cancer Registries Available from (https://apps.naaccr.org/explorer)

Rates are age-adjusted to the 2000 U.S. Standard Population

* Among females, several cancers had statistically significant lower or higher incidence rates in Massachusetts than in the US between 2015 and 2019. Only those with statistically significant differences are presented in the next two bullets:
  + Cancers with significantly lower incidence rates included cervical cancer, kidney, liver, colon and rectum, myeloma, and leukemia.
  + Cancers with significantly higher incidence rates included all cancers combined, thyroid, urinary bladder, esophagus, lung and bronchus, hodgkin lymphoma, brain, breast, and uterus.

Source: Massachusetts Cancer Registry, SEER\*Stat

Rates are age-adjusted to the 2000 U.S. Standard Population

* In general cancer incidence rates have decreased in Massachusetts between 2000 and 2019 while the total number of cancers (cancer counts) have increased during this period.
* Incidence rates for all cancers combined decreased from 518.3 per 100,000 in 2000 to 433.2 per 100,000 in 2019 while the number of cancer cases increased from 34,463 to 38,013.
* The rise in new cancer cases is mostly due to an aging and growing Massachusetts population.[[25]](#endnote-25)

Source: Massachusetts Cancer Registry

* Between 2015 and 2019 incidence rates for all cancers combined in Massachusetts have remained unchanged for males and slightly decreased for females.
* Incidence rates for all cancers combined were significantly lower in females than in males. For instance, in 2015 the overall cancer incidence rate was 457.0 per 100,000 among females and 493.3 per 100,000 among males.
* In 2019 the incidence rates had decreased to 448.9 per 100,000 for females and increased to 510.4 per 100,000 for and males but the increase and decrease were not statistically significant.

**Cancer Mortality**

|  |  |  |  |
| --- | --- | --- | --- |
| Table 2. Cancer Deaths by Sex for Leading Sites in Massachusetts, 2015-2019 | | | |
| **FEMALE** |  | |  |
| **CANCER SITE** | **NUMBER OF DEATHS** | | **% OF ALL CANCER DEATHS** |
| Lung and Bronchus | 7,824 | | 25.2 |
| Breast | 4,015 | | 12.9 |
| Pancreas | 2,496 | | 8.0 |
| Colon and Rectum | 2,406 | | 7.7 |
| Ovary | 1,567 | | 5.0 |
| Corpus Uteri & Uterus, NOS | 1,189 | | 3.8 |
| Leukemia | 1,061 | | 3.4 |
| Non-Hodgkin Lymphoma | 1,009 | | 3.3 |
| Liver & intrahepatic Bile Duct | 886 | | 2.9 |
| Brain & Other Nervous System | 858 | | 2.8 |
| All others | 7,775 | | 25.0 |
| **TOTAL** | **31,086** | | **100.0** |
| **MALES** | |  |  | |  |
| **CANCER SITE** | | **NUMBER OF DEATHS** | **% OF ALL CANCER DEATHS** | |  |
| Lung and Bronchus | | 7,589 | 23.4 | |  |
| Prostate | | 3,168 | 9.8 | |  |
| Pancreas | | 2,493 | 7.7 | |  |
| Colon and Rectum | | 2,461 | 7.6 | |  |
| Liver & intrahepatic Bile Duct | | 1,939 | 6.0 | |  |
| Esophagus | | 1,513 | 4.7 | |  |
| Urinary Bladder | | 1,452 | 4.5 | |  |
| Leukemia | | 1,372 | 4.2 | |  |
| Non-Hodgkin Lymphoma | | 1,164 | 3.6 | |  |
| Brain & Other Nervous System | | 1,107 | 3.4 | |  |
| All others | | 8,245 | 25.4 | |  |
| **TOTAL** | | **32,503** | **100.0** | |  |

Source: Massachusetts Registry of Vital Records and Statistics

For more information, visit the Massachusetts Cancer Registry Web Query at: <https://www.cancer-rates.info/ma/>

* Lung and bronchus cancer was the leading causes of cancer deaths in Massachusetts females, accounting for a quarter (25.2%) of all cancer deaths between 2015 and 2019.
* Other leading causes of cancer deaths in females included breast (12.9%), pancreas (8.0%), colon and rectum (7.7%), and ovary (5.0%).
* Among males, lung and bronchus cancer was also the leading cause of cancer deaths, with nearly one in four (23.4%) of all cancer deaths, followed by prostate (9.8%), pancreas (7.7%), colon and rectum (7.6%), and liver and intrahepatic bile duct (5.9%) cancers.

Source: Massachusetts Registry of Vital Records and Statistics

* Between 2015 and 2019 lung and bronchus cancer was the leading cause of cancer deaths in both Massachusetts females and males, with age-adjusted mortality rates of 32.0 per 100,000 and 40.9 per 100,000, respectively.
* In addition, breast, pancreatic, colon and rectum, and ovarian cancers were among the top cancers in females while prostate, colon and rectum, pancreatic, and liver cancers were among the leading causes of cancer deaths in males.

Source: Massachusetts Registry of Vital Records and Statistics

* Mortality rates were highest in the 65-74 and 75-84 age groups in both males and females between 2015 and 2019.
* Females had a greater proportion of deaths in the 85 and above age group compared to males (23.5% vs. 19.1%), respectively.
* Less than three percent of all deaths in both males and females occurred in those aged less than 45 years of age.

Source: Massachusetts Registry of Vital Records and Statistics, SEER\*Stat

Rates are age-adjusted to the 2000 U.S. Standard Population

* The mortality rate and the number of deaths for all cancers combined significantly decreased between 2000 and 2019 in Massachusetts.
* Mortality decreased from 206.3 per 100,000 in 2000 to 139.6 per 100,000 in 2019, and the number of cancer deaths per year decreased from 14,027 in 2000 to 12,582 in 2019.
* The decline in mortality rates and number of deaths is attributed to the decrease in smoking and advances in cancer screening and treatment.[[26]](#endnote-26)

Source: Massachusetts Registry of Vital Records and Statistics

* Between 2015 and 2019 the mortality rate for all cancers combined in Massachusetts significantly decreased by 1.8% annually from 182.3 per 100,000 to 169.9 per 100,000 in males.
* The mortality rate for all cancers combined in Massachusetts females also significantly decreased by 2.7% annually from 135.0 to 120.8 per 100,000.

Stage at Diagnosis for Selected Cancers[[27]](#endnote-27)

Figure 15. Breast Cancer Stage at Diagnosis in Massachusetts, 2015-2019

* Nearly four in five (79%) of breast cancers among Massachusetts females between 2015 and 2019 were diagnosed early (in situ or at a local stage).
* Seventeen percent of breast cancers among Massachusetts females were diagnosed at a regional stage and 3% at a distant stage.
* The relative survival for breast cancer when it is diagnosed early is 99 percent compared to 30.1 percent when diagnosed at a distant stage.

Source: Massachusetts Cancer Registry

Figure 16. Prostate Cancer Stage at Diagnosis in Massachusetts, 2015-2019

* Almost three in four (73%) of prostate cancers among Massachusetts males between 2015 and 2019 were diagnosed at a local stage and 15 percent at a regional stage.
* Seven percent of prostate cancers among Massachusetts males were diagnosed at a distant stage.
* The relative survival for prostate cancer when it is diagnosed early is 100 percent compared to 32.3 percent when diagnosed at a distant stage.

Source: Massachusetts Cancer Registry

Source: Massachusetts Cancer Registry

* Almost four in ten (38.5%) of colon and rectum cancers in Massachusetts between 2015 and 2019 were diagnosed at a local stage and 35.2% were diagnosed at a regional stage.
* One in five (18.9%) of colon and rectum cancers in Massachusetts were diagnosed at a distant stage.
* The relative survival for colon and rectum cancers when it is diagnosed early is 90.9 percent compared to 15.1 percent when it is diagnosed late.

Figure 17. Colon and Rectum Cancer Stage at Diagnosis in Massachusetts, 2015-2019

Figure 18. Lung and Bronchus Cancer Stage at Diagnosis in Massachusetts, 2015-2019

* Almost one third (32.2%) of lung and bronchus cancers in Massachusetts between 2015 and 2019 were diagnosed at a local stage.
* Over one in five (22.3%) of lung and bronchus cancers in Massachusetts were diagnosed at a regional stage and 39.4 percent at a distant stage.
* The relative survival for lung and bronchus cancers when it is diagnosed early is 61.2% compared to 7.0 percent when it is diagnosed late (at a distant stage).


Source: Massachusetts Cancer Registry

Cancer Incidence and Mortality in Massachusetts by County

Figure 19. Incidence Rates for all Cancer Sites in Massachusetts

by County, 2015-2019

* Cancer incidence rates in Massachusetts varied by county between 2015-2019.
* Counties with the highest incidence rates included:
  + Dukes
  + Nantucket
  + Plymouth
* Incidence rates in these three counties were greater than the state rate of 467.2 per 100,000.
* Counties with the lowest cancer incidence were:
  + Suffolk
  + Middlesex
  + Franklin
  + Hampshire




Source: Massachusetts Cancer Registry

MCR Web Query Tool: <https://www.cancer-rates.info/ma/>

Figure 20. Mortality Rates for all Cancer Sites in Massachusetts

by County, 2015-2019

* Cancer mortality rates in Massachusetts varied by county between 2015-2019.
* Counties with the highest mortality rates were:
  + Bristol
  + Worcester
  + Hampden
* Mortality rates in the three counties were greater than the state rate of 146.8 per 100,000.
* Counties with the lowest cancer mortality rates were:
  + Dukes
  + Nantucket
  + Essex
  + Middlesex



Source: Massachusetts Registry of Vital Records and Statistics

MCR Web Query Tool: <https://www.cancer-rates.info/ma/>

**Cancer Disparities and Health Equity**

Figure 21. Age-Adjusted Cancer Incidence Rates in Massachusetts by Sex and Race/Ethnicity, 2015-2019

Source: Massachusetts Cancer Registry

**Females Incidence**

* + White non-Hispanic (NH) females had significantly higher age-adjusted incidence rates of all cancers combined than Black NH, Asian NH, and Hispanic females.
  + Black non-Hispanic (NH) females had significantly higher age-adjusted incidence rates of all cancers combined than Asian NH, and Hispanic females.
  + Asian NH females had the lowest age-adjusted incidence rate for all cancers combined than other racial/ethnic groups.

**Males Incidence**

* Among males, Black NH and White NH had significantly higher age-adjusted incidence rates for all cancers combined than Asian NH and Hispanic males.
* There was no significant difference in the incidence rates for all cancers combined between White NH and Black NH males.
* Asian NH males had the lowest age-adjusted incidence rate for all cancers combined.

Figure 22. Age-Adjusted Cancer Mortality Rates in Massachusetts by Sex and Race/Ethnicity 2015-2019

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | |  | |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |

Source: Massachusetts Registry of Vital Records and Statistics

**Females Mortality**

* White NH females had the highest mortality rate for all cancers combined, significantly higher than for Asian NH, Black NH, and Hispanic females.
* Black NH females had significantly higher mortality rate for all cancers combined than Asian NH and Hispanic females.
* Asian NH females had the lowest mortality rate for all cancers combined compared to other racial/ethnic groups.

**Males Mortality**

* White NH males had significantly higher mortality rate for all cancers combined than all other racial/ethnic groups.
* Black NH males had significantly higher mortality rate for all cancers combined than Asian NH and Hispanics males.
* Asian NH and Hispanic males had the lowest mortality rate for all cancers combined compared to other racial/ethnic groups.

Source: Massachusetts Cancer Registry

* Black NH males had higher incidence rates of prostate cancer (185.4 per 100,000) and colon and rectum cancer (44.0 per 100,000) than other racial/ethnic groups.
* Prostate cancer incidence among Black NH males was more than one and half times higher than rates in White NH males (185.4 per 100,000 vs. 111.4 per 100,000).
* White NH males had higher incidence rates of lung and bronchus cancer (66.3 per 100,000), urinary bladder (40.6 per 100,000), and melanoma of the skin (30.6 per 100,000) compared to other racial/ethnic groups.

Source: Massachusetts Cancer Registry

* White NH females had higher incidence rates of breast cancer (144.9 per 100,000) and lung and bronchus cancer (63.7 per 100,000), than other racial/ethnic groups.
* Black NH (30.9 per 100,000) and White NH (30.4 per 100,000) females had higher incidence rates of colon and rectum cancer than Asian NH and Hispanic females.
* White NH (30.1 per 100,000) and Black NH (27.7 per 100,000) females had higher incidence rates of corpus uteri and uterus cancer than Asian NH and Hispanic females.
* Asian NH females had higher incidence rates of thyroid cancer (27.2 per 100,000) than other racial/ethnic groups.

Source: Massachusetts Cancer Registry

* Among females, incidence rates for all cancers combined in Massachusetts decreased by 1.0% annually between 2015-2019. However, this decrease was not statistically significant.
* Among males, incidence rates for all cancers combined in Massachusetts increased non-significantly by 0.5% annually between 2015-2019.
* There were no significant decreases in cancer incidence rates by race/ethnicity in both Massachusetts males and females between 2015 and 2019 except for Asian NH males whose incidence decreased by 2.4% per year.

Source: Massachusetts Registry of Vital Records and Statistics

* Among Massachusetts females, the mortality rate for all cancers combined significantly decreased by 2.7% per year between 2015 and 2019.
* There were significant decreases of 2.6% and 3.8% annually in all cancers combined mortality rates among White NH and Black NH females, respectively during this period.
* There were no significant decreases in cancer mortality rates among Asian NH, and Hispanic females.
* The mortality rate for all cancers combined decreased by 1.8% annually among Massachusetts males between 2015 and 2019.
* White NH males saw a significant decrease of 1.8% per year in mortality rate during this period.
* There were no significant decreases in cancer mortality rates in Black NH, Asian NH, and Hispanic males.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 3. Ten Most Common Causes of Cancer Deaths Among Massachusetts Females by Race/Ethnicity, 2015-2019 | | | | | | | | |
| **Rank** | **White non-Hispanic** | **Rate\*** | **Black non-Hispanic** | **Rate** | **Asian non-Hispanic** | **Rate** | **Hispanic** | **Rate** |
| 1 | Lung & bronchus | 34.4 | Lung & bronchus | 18.9 | Lung & bronchus | 17.9 | Lung & bronchus | 12.4 |
| 2 | Breast | 17.1 | Breast | 18.4 | Breast | 9.2 | Breast | 11.8 |
| 3 | Pancreas | 10.3 | Pancreas | 10.9 | Pancreas | 6.6 | Pancreas | 7.0 |
| 4 | Colon & rectum | 10.0 | Colon & rectum | 8.6 | Colon & rectum | 6.3 | Colon & rectum | 7.0 |
| 5 | Ovary | 6.9 | Uterus | 8.1 | Liver | 4.8 | Liver | 5.5 |
| 6 | Uterus | 4.8 | Ovary | 4.9 | Stomach | 4.3 | Uterus | 4.3 |
| 7 | Leukemia | 4.5 | Liver | 4.3 | Ovary | 3.8 | Stomach | 4.1 |
| 8 | Brain | 4.2 | Myeloma | 4.2 | NHL | 2.6 | Ovary | 3.3 |
| 9 | NHL | 4.1 | Stomach | 3.3 | Leukemia | 1.9 | NHL | 3.2 |
| 10 | Liver | 3.4 | NHL | 3.2 | Cervix | 1.7 | Leukemia | 3.0 |
| Source: Massachusetts Registry of Vital Records and Statistics | | | | | |  |  |  |
| NHL= Non-Hodgkin Lymphoma  Age-adjusted mortality rate per 100,000 | | | |  |  |  |  |  |
|  |  |  |  |  |
| Color-coded table by cancer type showing the age-adjusted mortality rates for the top ten cancers for each race/ethnic group. | | | | | | | | |

* Among Massachusetts females, lung and bronchus cancer was the most common cause of cancer deaths in all racial/ethnic groups.
* Breast cancer was the second most common cause of all cancer deaths in all racial/ethnic groups.
* Pancreatic cancer was the third most common cause of cancer deaths in all racial/ethnic groups.
* Colon and rectum cancer was the fourth most common cause of all cancer deaths in all racial/ethnic groups.
* Ovarian cancer mortality varied greatly among the different racial/ethnic groups. It was the fifth leading cause of cancer deaths in White NH, the sixth in Black NH, the seventh in Asian NH, and eighth in Hispanic females.
* Uterus cancer was the fifth leading cause of cancer deaths in Black NH females and the sixth in White NH and Hispanic females.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 4. Ten Most Common Causes of Cancer Deaths Among Massachusetts Males by Race/Ethnicity, 2015-2019 | | | | | | | | |  |
| **Rank** | **White non-Hispanic** | **Rate\*** | **Black non-Hispanic** | **Rate** | **Asian non-Hispanic** | **Rate** | **Hispanic** | **Rate** |  |
| 1 | Lung & bronchus | 42.6 | Prostate | 34.6 | Lung & bronchus | 33.7 | Lung & bronchus | 19.7 |  |
| 2 | Prostate | 18.2 | Lung & bronchus | 32.0 | Liver | 14.8 | Prostate | 16.4 |  |
| 3 | Colon & rectum | 13.7 | Colon & rectum | 16.2 | Colon & rectum | 8.1 | Liver | 13.5 |  |
| 4 | Pancreas | 13.7 | Pancreas | 15.1 | Stomach | 7.4 | Colon & rectum | 8.7 |  |
| 5 | Bladder | 8.9 | Liver | 12.5 | Prostate | 6.7 | Stomach | 7.0 |  |
| 6 | Liver | 8.9 | Stomach | 6.8 | Pancreas | 6.2 | Pancreas | 6.4 |  |
| 7 | Esophagus | 8.6 | Myeloma | 6.2 | NHL | 4.3 | NHL | 4.9 |  |
| 8 | Leukemia | 8.2 | Esophagus | 4.7 | Oral Cavity | 4.0 | Leukemia | 4.7 |  |
| 9 | NHL | 6.9 | Bladder | 4.6 | Leukemia | 3.9 | Bladder | 3.4 |  |
| 10 | Brain | 6.4 | Leukemia | 3.8 | Esophagus | 3.4 | Esophagus | 3.2 |  |
| Source: Massachusetts Registry of Vital Records and Statistics | | | | |  |  |  |  |  |
| NHL= Non-Hodgkin Lymphoma  \*Age-adjusted mortality rate per 100,000 | | | | | |  |  |  |  |
|  |  |  |  |
| Color-coded table by cancer type showing the age-adjusted mortality rates for the top ten cancers for each  race/ethnic group. | | | | | | | | | |

* Among Massachusetts males, lung and bronchus cancer was the most common cause of cancer deaths in all racial/ethnic groups, except in Black non-Hispanics (NH) where prostate cancer was leading cause of cancer deaths.
* Prostate cancer was the second most common cause of cancer deaths in White NH and Hispanic males, and the fifth among Asian NH males.
* Colon and rectum cancer was the third most common cause of cancer deaths in all racial/ethnic groups except, in Hispanic males, where it was the fourth most common cause of cancer deaths.
* Pancreatic cancer was the fourth most common cause of cancer deaths in White NH and Black NH males and the sixth leading cause of cancer deaths in Asian NH and Hispanic males.
* Bladder cancer was the fifth leading cause of cancer deaths in White NH and the ninth in Black NH and Hispanic males.
* Liver cancer was the second leading cause of cancer deaths in Asian NH males. It was also the third most common cause of cancer deaths in Hispanics, the fifth in Black NH, and the sixth in White NH males.

**Data Sources and Online Visualization Tools**

* Massachusetts Cancer Registry (MCR): <https://www.mass.gov/massachusetts-cancer-registry>

The MCR website offers a wide variety of statistical products, including statewide reports, city and town series, and special reports. It also includes abstracting and coding manuals as well as Massachusetts Cancer Registry edits.

* MCR Web Query Tool: <https://www.cancer-rates.info/ma/>

The MCR web query tool allows users to customize cancer incidence and mortality rate tables and maps by cancer site, sex, time frame, and race/ ethnicity.

* CDC/NCI State Cancer Profiles: <https://statecancerprofiles.cancer.gov/>

State Cancer Profiles provides dynamic views demographic and cancer data including screening and risk factors, incidence, prevalence, and mortality for prioritizing cancer control efforts at the national, state, and local levels.

* Cancer Control P.L.A.N.E.T: <https://cancercontrolplanet.cancer.gov/planet/>

Cancer Control P.L.A.N.E.T. portal provides access to data and resources that can help planners, program staff, and researchers design, implement and evaluate evidence-based cancer control programs.

* U.S. Cancer Statistics Data Visualizations Tool: <https://www.cdc.gov/cancer/uscs/dataviz/index.htm>

The Data Visualizations tool provides information on the numbers and rates of new cancer cases and deaths at the national, state, and county levels. The tool also provides cancer data by sex, age, race and ethnicity, trends over time, stage at diagnosis, survival by stage, and prevalence. Screening data for breast, colon and rectum, and cervical cancer, and risk factors such as (obesity, nutrition, physical inactivity, tobacco use, and alcohol consumption) are estimated from BRFSS. In addition, [Human papillomavirus (HPV) vaccination coverage](https://urldefense.com/v3/__https:/gis.cdc.gov/Cancer/USCS/*/HPVVaccination/__;Iw!!CUhgQOZqV7M!xORy2rgm8HNtfFMazEQ5_CXsPH-RdRGzaXrUmKT7Bsl9FlCRHOYPd1RPwSdXpHrXv9m5Vg$) estimates from the National Immunization Survey-Teen are provided.

* Cancer Statistics Website: <https://cancerstatisticscenter.cancer.org/#!/>

The Cancer Statistics Center website is primarily based on the data and analysis provided in the American Cancer Society’s annual Cancer Statistics paper, published in CA: A Cancer Journal for Clinicians, and its consumer-friendly companion report, Cancer Facts & Figures.

* CiNA Explorer: <https://apps.naaccr.org/explorer/>

CiNA Explorer is an interactive tool that provides easy access to a wide range of NAACCR cancer statistics. Detailed statistics are available for a NAACCR region or registry by cancer site, gender, race, calendar year, age, and stage.

* SEER\*Explorer: <https://seer.cancer.gov/statistics-network/explorer/overview.html> SEER\*Explorer is an interactive website that provides easy access to a wide range of SEER cancer statistics at the national level. Detailed statistics are available for a cancer site by sex, race, calendar year, age, and for a selected number of cancer sites, by stage and histology.

**Appendices**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Appendix I. New Cancer Cases and Incidence Rates by Cancer Site and Sex, Massachusetts, 2015-2019** | | | | | | |
|  | **Male** | | **Female** | | **Total** | |
|  | **Cases** | **Rate** | **Cases** | **Rate** | **Cases** | **Rate** |
| **All Cancer Sites** | **97,311** | **501.5** | **100,698** | **446.7** | **198,048** | **467.2** |
| Brain & Other Nervous System | 1,512 | 8.3 | 1,240 | 6.1 | 2,753 | 7.1 |
| Breast | 268 | 1.4 | 30,412 | 138.9 | \* | \* |
| Breast In situ | 38 | 0.2 | 7,898 | 37.6 | \* | \* |
| Cervical Cancer | \* | \* | 1,032 | 5.4 | \* | \* |
| Colon & Rectum | 7,210 | 38.5 | 6,896 | 29.9 | 14,108 | 33.8 |
| Corpus Uterus | \* | \* | 7,015 | 29.7 | \* | \* |
| Esophagus | 1,826 | 9.3 | 539 | 2.2 | 2,365 | 5.4 |
| Hodgkin Lymphoma | 557 | 3.2 | 488 | 2.7 | 1,047 | 2.9 |
| Kidney & Renal Pelvis | 4,325 | 22.3 | 2,393 | 10.5 | 6,720 | 15.9 |
| Larynx | 1,035 | 5.1 | 272 | 1.2 | 1,308 | 2.9 |
| Leukemia | 3,121 | 17.1 | 2,289 | 10.3 | 5,412 | 13.3 |
| Liver & Intrahepatic Bile Ducts | 2,865 | 14.1 | 1,039 | 4.3 | 3,906 | 8.8 |
| Lung & Bronchus | 12,381 | 64.4 | 14,345 | 59.3 | 26,729 | 61.2 |
| Melanoma of the Skin | 5,570 | 29.8 | 4,410 | 20.2 | 9,980 | 24.1 |
| Multiple Myeloma | 1,642 | 8.6 | 1,282 | 5.3 | 2,924 | 6.8 |
| Non-Hodgkin Lymphoma | 4,487 | 24.0 | 3,647 | 15.9 | 8,138 | 19.4 |
| Oral Cavity & Pharynx | 3,661 | 18.1 | 1,567 | 6.8 | 5,228 | 12.0 |
| Ovary | \* | \* | 2,297 | 10.2 | \* | \* |
| Pancreas | 3,130 | 16.2 | 2,947 | 12.2 | 6,077 | 14.0 |
| Prostate | 24,614 | 116.9 | \* | \* | \* | \* |
| Stomach | 1,714 | 9.0 | 1,057 | 4.6 | 2,772 | 6.5 |
| Testis | 952 | 5.8 | \* | \* | \* | \* |
| Thyroid | 1,833 | 10.0 | 4,893 | 25.9 | 6,729 | 18.1 |
| Urinary Bladder | 7,042 | 37.9 | 2,549 | 10.5 | 9,592 | 22.2 |
| Other Sites | 7,566 | 41.4 | 8,089 | 34.6 | 15,661 | 37.4 |
| Rates are age-adjusted to the 2000 U.S. Standard Population, per 100,000 total population | | | | |  |  |
| Breast in situ is excluded from “All Cancer Sites” | |  |  |  |  |  |
| \*Cancers found in only one sex or predominantly in one sex (breast cancer). | | | |  |  |  |
| Total includes persons classified as a transgender and persons of unknown sex | | | | |  |  |
| Source: Massachusetts Cancer Registry |  |  |  |  |  |  |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Appendix II. Number of Cancer Deaths and Death Rates by Cancer Site and Sex, Massachusetts, 2015-2019** | | | | | | |
|  | **Male** | | **Female** | | **Total** | |
|  | **Deaths** | **Rate** | **Deaths** | **Rate** | **Deaths** | **Rate** |
| **All Cancer Sites** | **32,503** | **177.7** | **31,086** | **127.6** | **63,589** | **147.9** |
| Brain & Other Nervous System | 1,107 | 5.9 | 858 | 3.8 | 1,965 | 4.8 |
| Breast | 44 | 0.2 | 4,015 | 16.9 | \* | \* |
| Lung & Bronchus | 7,589 | 40.9 | 7,824 | 32.0 | 15,413 | 35.7 |
| Cervical Cancer | \* | \* | 238 | 1.1 | \* | \* |
| Colon & Rectum | 2,461 | 13.5 | 2,406 | 9.7 | 4,867 | 11.4 |
| Corpus Uterus | \* | \* | 1,189 | 4.9 | \* | \* |
| Esophagus | 1,513 | 7.9 | 416 | 1.7 | 1,929 | 4.4 |
| Hodgkin Lymphoma | 55 | 0.3 | 42 | 0.2 | 97 | 0.2 |
| Kidney & Renal Pelvis | 801 | 4.3 | 467 | 1.8 | 1,268 | 2.9 |
| Larynx | 265 | 1.4 | 84 | 0.3 | 349 | 0.8 |
| Leukemia | 1,372 | 7.8 | 1,061 | 4.3 | 2,433 | 5.8 |
| Liver & Intrahepatic Bile Ducts | 1,939 | 9.8 | 886 | 3.6 | 2,825 | 6.4 |
| Melanoma of Skin | 588 | 3.3 | 363 | 1.5 | 951 | 2.2 |
| Multiple Myeloma | 709 | 4.0 | 558 | 2.2 | 1,267 | 2.9 |
| Non-Hodgkin Lymphoma | 1,164 | 6.7 | 1,009 | 4.1 | 2,173 | 5.2 |
| Oral Cavity & Pharynx | 683 | 3.5 | 325 | 1.3 | 1,008 | 2.3 |
| Ovary | \* | \* | 1,567 | 6.6 | \* | \* |
| Pancreas | 2,493 | 13.3 | 2,496 | 10.1 | 4,989 | 11.5 |
| Prostate | 3,168 | 18.5 | \* | \* | \* | \* |
| Stomach | 752 | 4.1 | 490 | 2.1 | 1,242 | 2.9 |
| Testis | 35 | 0.2 | \* | \* | \* | \* |
| Thyroid | 97 | 0.5 | 128 | 0.5 | 225 | 0.5 |
| Urinary Bladder | 1,452 | 8.3 | 602 | 2.3 | 2,054 | 4.7 |
| Other Sites | 4,216 | 23.2 | 4062 | 16.6 | 8,278 | 19.3 |
| Rates are age-adjusted to the 2000 U.S. Standard Population, per 100,000 total population | | | | |  |  |
| \*Cancers found in only one sex or predominantly in one sex (breast cancer). | | | |  |  |  |
| Total includes persons classified as a transgender and persons of unknown sex | | | | |  |  |
| Source: Massachusetts Registry of Vital Records and Statistics | | | | | | |

**Appendix III. Technical Notes and Definitions**

**Population Estimates:** Population estimates used for this report were developed by the University of Massachusetts Donahue Institute (UMDI) in partnership with the Massachusetts Department of Public Health, Bureau of Environmental Health.

**Race/Ethnicity:** The MCR collects reports of newly diagnosed cases of cancer from Massachusetts health care facilities and providers who diagnose or treat patients. Race and ethnicity data are obtained from the medical record, which may be self-reported by a patient or noted by a patient’s provider. The MCR uses an algorithm developed by NAACCR called the NAACCR Hispanic Identification Algorithm (NHIA) to help classify Hispanic ethnicity. The algorithm is only applied to cases with an unknown Spanish/Hispanic origin or cases that have been classified as Hispanic based on a Spanish surname only. The algorithm uses last name, maiden name, birthplace, race, and sex to determine the ethnicity of these cases.

The race/ethnicity categories presented in this report are mutually exclusive. Cases and deaths are only included in one race/ethnicity category. The race/ethnicity tables and figures include the categories White non-Hispanic, Black non-Hispanic, Asian non-Hispanic, and Hispanic. The total population in Massachusetts also includes unknown races/ethnicities and Native Americans. As a result, the number of cases for the total population is not the sum of cases by race/ethnicity presented in the tables and figures.

**Age-Adjusted Rates:** A weighted average of the age-specific rates, where the weights are the proportions of persons in the corresponding age groups of the standard population. The 2000 U.S. Census Bureau population distribution was used as the standard. Rates were age-adjusted using nineteen 5-year age groups (<1, 1-4, 5-9, 10-14, 15-19 ... 85+). Age-adjusted rates can only be compared if they are adjusted to the same population.

**Age-specific rate:** A rate among people of a particular age range in a given time period. In this report, age-specific rates were calculated by dividing the number of people in an age group who were newly diagnosed with cancer (incidence) or died of cancer (mortality) by the number of people in that same age group overall.

**Incidence:** The number of people who are newly diagnosed with a disease, condition, or illness during a particular time period. The incidence data presented in this report were coded using the International Classification of Disease for Oncology 3rd Edition (ICD-O-3) coding system.

**Mortality:** The number of people who died of a disease, condition, or illness during a particular time period. The mortality data presented in this report were coded using the International Classification of Diseases Tenth Revision (ICD-10).

**Annual Percent Change (APC):** A statistical method for trend analysis. It shows how much a cancer has increased or decreased over the observed period of time. This estimation assumes that the change in incidence and mortality is constant during the observed period. Trends in the age-standardized incidence and mortality rates in this report were analyzed using **Jointpoint regression,** a windows-based statistical software provided by NCI/SEER that calculates the number and location of points where trends change directions (jointpoints).

**Statistically Significant**: Results were considered to be statistically significant when the p value was less than or equal to 0.05.

**ICD codes used for this report**

|  |  |  |
| --- | --- | --- |
| **Cancer Site/Type** | **ICD-O-3 SEER Site Recode\*** | **ICD-10\*\*** |
| Brain & Other Nervous System | 31010, 31040 | C70-C72 |
| Breast (includes *in situ*) | 26000 | C50 |
| Lung and Bronchus | 22030 | C34 |
| Cervix Uteri | 27010 | C53 |
| Colon & Rectum | 21041-21052 | C18-C20, C26.0 |
| Corpus Uteri & Uterus, NOS | 27020, 27030 | C54-C55 |
| Esophagus | 21010 | C15 |
| Hodgkin Lymphoma | 33011, 33012 | C81 |
| Kidney & Renal Pelvis | 29020 | C64-C65 |
| Larynx | 22020 | C32 |
| Leukemia | 35011-35013, 35021, 35031, 35022, 35023, 35041, 35043 | C90.1, C91 – C95 |
| Liver and Intrahepatic Bile Ducts | 21071 | C22 |
| Melanoma of Skin | 25010 | C43 |
| Multiple Myeloma | 34000 | C90.0, C90.2 |
| Non – Hodgkin Lymphoma | 33041, 33042 | C82-C85, C96.3 |
| Oral Cavity & Pharynx | 20010-20100 | C00-C14 |
| Ovary | 27040 | C56 |
| Pancreas | 21100 | C25 |
| Prostate | 28010 | C61 |
| Stomach | 21020 | C16 |
| Testis | 28020 | C62 |
| Thyroid | 32010 | C73 |
| Urinary Bladder (includes *in situ*) | 29010 | C67 |

**\***International Classificationof Diseases for Oncology, 3rd Ed. Surveillance, Epidemiology, and End Results (SEER) Site Recode ICD-O-3/WHO 2008Definition:<https://seer.cancer.gov/siterecode/icdo3_dwhoheme/index.html>

**\*\****International Classification of Diseases, Tenth Revision* (includes codes added since publication) for mortality data

**Data Limitations**

When interpreting the cancer data, it is important to consider certain limitations which include:

* Under-reporting in areas close to neighboring states: Although the MCR has reciprocal reporting agreements with 42 states, there may still be some Massachusetts residents who were diagnosed out of state and not reported to the MCR.
* Interpretation of trends: Apparent increases or decreases in cancer incidence over time may reflect changes in diagnostic methods or case reporting rather than true changes in cancer occurrence.
* Small number of cases: Some calculations in this report involved small numbers of cases. As a result, differences in rates may be due to chance, and the data should be interpreted with caution.

**Appendix IV. DPH Cancer Programs Health Equity Initiatives**

**MA Statewide Cancer Plan**

The [Massachusetts Statewide 2017-2021 Cancer Plan](https://www.mass.gov/info-details/2017-2021-massachusetts-cancer-plan) sets forth a comprehensive cancer control blueprint for action to reduce the cancer burden in Massachusetts. It is designed as a guide for statewide, local, and community efforts in preventing and controlling cancer. The Plan addresses the social determinants and related risk factors that contribute to cancer in our communities by considering the policies, laws, and environments that impact our behavior and create social and physical environments that promote good health for all. The MA statewide cancer plan is intended for community health and faith-based coalitions, disease prevention and advocacy organizations, healthcare providers, researchers, policy makers, public health officials, cancer survivors, and individuals interested in cancer activities. The MA statewide cancer plan includes health equity and access as one of its cross-cutting themes to address root causes of cancer disparities and to achieve equity by increasing access to quality services, healthcare, and resources in a timely manner and creating environments for people to achieve their highest health potential.

**MA Colorectal Cancer Control Program’s CRC Learning Collaborative**


Although overall statewide colorectal cancer (CRC) screening rates are among the highest in the nation, disparities in CRC screening continue to persist among certain subpopulations in Massachusetts. According to the Massachusetts Behavioral Risk Factor Surveillance System (BRFSS), the overall CRC screening rate in Massachusetts in 2018 was 77.1%. At the state level there was no significant difference in colorectal cancer screening by race and ethnicity even though screening rates among Hispanics and Asian populations in Massachusetts were much lower at 68.3% among Hispanics and 70.0% in Asians, compared to 78.3% among Whites non-Hispanic and 79.9% among Black non-Hispanics adults. However, adults with less than high school education (66.5%) and those with less than $25,000 household income (67.5%) were less likely to be screened compared to adults with college or more education and with household income greater than $50,000. Similar disparities in CRC screening were observed among clients ages 51-75 receiving care in federally qualified health centers (FQHCs) where only 55.6% of patients were up to date with their CRC screening. These data also show that screening rates in FQHCs were over 20 percentage points lower than the state average. Within FQHCs, CRC screening rates ranged from 17.8%-80.5% in 2018. The MA Colorectal Cancer Control Program (CRCCP) works with the MA League of Community Health Centers (MLCHC) to help community health centers (CHCs) with low colorectal cancer screening rates to implement Community Guide recommended evidence-based interventions to increase CRC screening. Each participating CHC is coached through performing a disparities analysis on CRC screening rates by race/ethnicity/language to better understand gaps in care and then develop plans to decrease inequities that are identified.

**MA Comprehensive Cancer Control Program’s (MCCCP)**

Persistent inequities across the cancer care continuum from primary prevention to survivorship point to the need to 1) engage professionals from multiple sectors who work in different systems across the cancer continuum to align efforts and priorities, especially in focusing efforts on priority populations and 2) at each stage of the continuum, going beyond established “best practice” approaches to really understand the complex barriers and needs experienced by priority populations and working together with them to develop tailored solutions. Finally, geographic inequities underscore the need to have regional representation from across the state, especially areas with greater cancer burden, and developing regional solutions.

In 2021, after completing a qualitative assessment that indicated the MCCCP’s membership was largely Boston-based and hospital/clinical-focused, the MCCCP began restructuring its Network into a broader, statewide [Comprehensive Cancer Coalition](https://www.mass.gov/service-details/massachusetts-comprehensive-cancer-coalition). This Coalition structure was designed with input from stakeholders in cancer care across the state.

The reorganized structure is as follows:



The Coalition’s Leadership Group is comprised of Regional Champions from each region of MA and includes the Co-Chairs of the newly designed Health Equity Committees (HECs) organized across the cancer continuum (Primary Prevention, Secondary Prevention, Treatment and Diagnosis, Survivorship, and Palliative Care). Recruitment efforts are focused on increasing diverse membership within each HEC to include community-based and faith-based organizations, patients, caregivers, clinicians, academics, municipalities, and non-traditional partners to ensure diverse perspective as the Coalition develops the next 5-year State Cancer Plan. The Coalition’s new vision and mission, developed by the Leadership Group, are as follows:

*Vision*

To significantly reduce the burden of cancer for all residents of Massachusetts.

*Mission*

To develop partnerships that address the disparities across the cancer continuum and improve the lives of cancer survivors and those living with cancer.

* Identify and eliminate barriers to health equity to close persistent gaps in cancer outcomes
* Prioritize the unmet needs of disproportionately affected communities through advocacy, multisectoral partnerships, and ensuring equitable access to quality resources
* Work collaboratively to implement and promote the Massachusetts State Cancer Plan

An example of the MCCCP efforts to address the inequities in prostate cancer treatment outcomes in Black non-Hispanic men as specified in Massachusetts 2017-2021 State Cancer Plan is shown through its work with the Prostate Cancer Workgroup. One objective of the Massachusetts State Cancer plan was to conduct an in-depth analysis of the Massachusetts Cancer Registry (MCR) data to identify racial/ethnic disparities in the treatment of prostate cancer and to guide development of interventions aimed at ensuring equitable treatment for prostate cancer. The MCCCP worked with the MCR to conduct preliminary analysis of the MCR data and found that there were disparities in prostate cancer treatment between Black non-Hispanic and White non-Hispanic men in Massachusetts. Based on these findings, the MCR and MCCCP collaborated with the Prostate Cancer Workgroup to conduct an in-depth analysis of the MCR data and prepared a manuscript on [racial differences in the treatment and outcomes for prostate cancer in Massachusetts](https://doi.org/10.1002/cncr.33564) which was published in May 2021. The objective of the manuscript was to examine racial differences in the treatment and outcomes for prostate cancer in Massachusetts. The key finding of the study was that despite lower likelihood of definitive treatment, Black non-Hispanic men had better cancer specific survival than White non-Hispanic men both adjusted and unadjusted survival analyses.  The workgroup also published a manuscript on [trends in mortality among Black and White men with prostate cancer in Massachusetts and Pennsylvania: Race and neighborhood socioeconomic position](https://doi.org/10.1002/cncr.33506).

In addition, the Prostate Cancer Workgroup used MCCCP funding to support qualitative evaluation of the issues and key factors that contribute to the disparities in prostate cancer treatment for Black men in Massachusetts. The main goal of this study was to understand the reasons for the identified disparities in use of definitive prostate cancer treatment identified using quantitative data indicating that Black non-Hispanic men were less likely to receive definitive treatment of prostate cancer compared to White non-Hispanic men. The MCCCP and the Prostate Cancer Work Group hired JSI Research & Training Institute to conduct key informant interviews with Massachusetts prostate cancer providers and advocates regarding the perceived barriers to definitive prostate cancer treatment between Black non-Hispanic men and White non-Hispanic men. Key findings for the qualitative study included:

* There is a growing awareness that disparities in prostate cancer treatment may be more strongly associated with social determinants of health than biological factors.
* How care teams manage the “hand-off” of a patient from primary care to a specialist will have a significant effect on treatment decisions.
* Factors that affect prostate cancer treatment include access to care, health literacy, socio- economic status and financial concerns.
* Prostate cancer treatment decision-making is affected by factors such as medical and research mistrust, tolerance of side effects, shared decision-making, family support, and severity of disease.
* Disparities in prostate cancer treatment can be addressed through patient education, decision tools, improved communication, and the use of community health workers and patient navigators.

The prostate Cancer Workgroup is engaging with select Massachusetts hospitals to address inequities in prostate cancer treatment.

**MA Breast and Cervical Cancer Program**

The Massachusetts Breast and Cervical Cancer Program (MBCCP) uses a multi-pronged systems approach aimed at effectively reaching, engaging, and addressing the barriers women of color face in accessing essential preventive, diagnostic and treatment services in Massachusetts. This is accomplished through two key strategies including providing patient navigation to reduce institutional, provider-level, and community barriers; and supporting the use of evidence-based interventions through client reminders, small media, one on one and group education through community-based organizations, and provider reminders.The MBCCP works with CHCs that predominantly serve women residing in communities of color who face significant financial and structural barriers to accessing essential screening and diagnostic services. The MBCCP focuses on these centers because these are the safety net healthcare providers with the greatest ability to reach and provide culturally competent care to priority populations.

In the coming 5 years, the MBCCP will expand its equity-centered, best-practice approaches into more health systems by working collaboratively with the other DPH programs including the MCCCP, MCR, other chronic disease prevention programs, and the MLCHC to reach, enroll, and serve more women in the state and over time, close the gap in breast and cervical cancer inequities in Massachusetts. This approach will also support state goals of reducing disparities in chronic disease and associated risk factors through promotion of healthy behaviors, engaging partners and enhancing linkages in communities, policy influence, system improvement, knowledge generation, dissemination of information, provision of resources, and conducting surveillance monitoring. It will also allow for the exploration of future expansion of services to meet the needs of those most vulnerable across the state.

**MA Bureau of Environmental Health: Environmental Justice**

* Environmental Justice is the principle that all people have the right to be protected from environmental pollution, and to live in and enjoy a clean, healthy environment.
* The [DPH Environmental Justice Tool](https://mass.gov/dph/ej-tool) is an interactive online tool that facilitates use of the statewide [Environmental Justice Policy](https://www.mass.gov/environmental-justice). This policy was established to help address the disproportionate environmental burdens experienced by individuals of color and lower-income people.
  + Environmental Justice (EJ) neighborhoods are defined as those that meet one or more criteria based on median household income, neighborhood race and ethnicity make-up, and English language isolation.
  + Vulnerable health EJ criteria further identify populations with evidence of higher-than-average rates of environmentally-related health outcomes. These include heart attack hospitalizations, childhood blood lead levels, low birth weight, and childhood asthma emergency department visits.
* The [MA Environmental Public Health Tracking (EPHT) website](http://www.mass.gov/dph/matracking) hosts the DPH Environmental Justice Tool as well as many environmental and health datasets, including cancer incidence at the county, community, and census tract level.

**References**

1. Malignant disease and benign brain-related tumor registry; reports. Available at: <http://www.malegislature.gov/Laws/GeneralLaws/PartI/TitleXVI/Chapter111/Section111B> [↑](#endnote-ref-1)
2. American Cancer Society. Cancer Basics. What is Cancer? Available at: <https://www.cancer.org/cancer/cancer-basics/what-is-cancer.html> [↑](#endnote-ref-2)
3. National Cancer Institute. Available at: <https://www.cancer.gov/about-cancer/causes-prevention/patient-prevention-overview-pdq> [↑](#endnote-ref-3)
4. American Cancer Society. Cancer Facts and Figures 2023. Available at: <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf> [↑](#endnote-ref-4)
5. National Cancer Institute. Risk Factors for Cancer. Available at: <https://www.cancer.gov/about-cancer/causes-prevention/risk> [↑](#endnote-ref-5)
6. American Cancer Society. Cancer Facts and Figures 2023. Available at: <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf> [↑](#endnote-ref-6)
7. American Cancer Society. Cancer Facts and Figures 2023. Available at: <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf> [↑](#endnote-ref-7)
8. National Cancer Institute. Cancer Staging. Available at: <https://www.cancer.gov/about-cancer/diagnosis-staging/staging> [↑](#endnote-ref-8)
9. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Colon and rectum Cancer. Available at: <https://seer.cancer.gov/statfacts/html/colorect.html> [↑](#endnote-ref-9)
10. American Cancer Society. Cancer Facts and Figures 2022. Available at: <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf> [↑](#endnote-ref-10)
11. American Cancer Society. Diversity, Inclusion, and Equity in America. Available at: <http://pressroom.cancer.org/releases?item=908&_ga=2.125825354.1312072142.1633530743-909755451.1631827794> [↑](#endnote-ref-11)
12. National Cancer Institute. Cancer Disparities. Available at: <https://www.cancer.gov/about-cancer/understanding/disparities> [↑](#endnote-ref-12)
13. Centers for Disease Control and Prevention. What is Health Equity? Available at: <https://www.cdc.gov/healthequity/index.html> [↑](#endnote-ref-13)
14. Centers for Disease Control and Prevention. What is Health Equity? Available at: <https://www.cdc.gov/healthequity/index.html> [↑](#endnote-ref-14)
15. American Cancer Society. Cancer Facts and Figures 2023. Cancer Facts and Figures. Available at:

    <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf> [↑](#endnote-ref-15)
16. US Census. American Community Survey. Percent of Poverty in Massachusetts. 2019. Available at: <https://data.census.gov/cedsci/table?q=poverty%20in%20Massachusetts%20in%202019&tid=ACSST1Y2019.S1703>

    [poverty in Massachusetts in 2019 - Census Bureau Tables](https://data.census.gov/table?q=poverty+in+Massachusetts+in+2019) [↑](#endnote-ref-16)
17. American Cancer Society. Cancer Facts and Figures 2023. Cancer Facts and Figures. Available at:

    <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf> [↑](#endnote-ref-17)
18. Behavioral Risk Factor Surveillance System (BRFSS). Available at: [Behavioral Risk Factor Surveillance System | DPH | CDC"](https://nccd.cdc.gov/weat/#/) [↑](#endnote-ref-18)
19. Massachusetts Department of Public Health. A Profile of Health Among Massachusetts Adults, 2019. Behavioral Risk Factor Surveillance System. December 2020. Available at: <https://www.mass.gov/doc/a-profile-of-health-among-massachusetts-adults-2019/download> [↑](#endnote-ref-19)
20. American Cancer Society. Cancer Facts and Figures 2023. Cancer Facts and Figures. Available at:

    <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf> [↑](#endnote-ref-20)
21. Zavala VA, Bracci PM, Carethers JM, et al. Cancer health disparities in racial/ethnic minorities in the United States. Br J Cancer. 2021;124: 315-332 [↑](#endnote-ref-21)
22. Pampel FC, Krueger PM, Denney JT. Socioeconomic disparities in health behaviors. Ann Rev Oncol. 2010;36: 349-370. [↑](#endnote-ref-22)
23. Clegg LX, Reichman ME, Miller BA, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National

    Longitudinal Mortality Study. Cancer Causes Control. 2009;20: 417-435. [↑](#endnote-ref-23)
24. Zavala VA, Bracci PM, Carethers JM, et al. Cancer health disparities in racial/ethnic minorities in the United States. Br J Cancer. 2021;124: 315-332 [↑](#endnote-ref-24)
25. Weir HK, Thompson TD, Stewart SL, White MC. Cancer Incidence Projections in the United States Between 2015 and 2050. Prev Chronic Dis 2021;18:210006. DOI: <http://dx.doi.org/10.5888/pcd18.210006> external icon [↑](#endnote-ref-25)
26. Centers for Disease Control and Prevention. Cancer Research. An Update on Cancer Deaths in the United States. Available at: <https://www.cdc.gov/cancer/dcpc/research/update-on-cancer-deaths/index.htm> [↑](#endnote-ref-26)
27. Cancer Institute. Cancer Stat Facts: Breast, Prostate, Colorectal, and Lung and Bronchus. Available at:

    <https://seer.cancer.gov/statfacts/html/breast.html>

    <https://seer.cancer.gov/statfacts/html/prost.html>

    <https://seer.cancer.gov/statfacts/html/colorect.html>

    <https://seer.cancer.gov/statfacts/html/lungb.html> [↑](#endnote-ref-27)